1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS (2014) The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16 (7):896-913. doi:10.1093/neuonc/nou087
2. Chen R, Smith-Cohn M, Cohen AL, Colman H (2017) Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics 14 (2):284-297. doi:10.1007/s13311-017-0519-x
3. Hirtz A, Rech F, Dubois-Pot-Schneider H, Dumond H (2020) Astrocytoma: A Hormone-Sensitive Tumor? Int J Mol Sci 21 (23). doi:10.3390/ijms21239114
4. Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS (2019) Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? Am Soc Clin Oncol Educ Book 39:133-145. doi:10.1200/EDBK_238353
5. Kulac I, Tihan T (2019) Pilomyxoid astrocytomas: a short review. Brain Tumor Pathol 36 (2):52-55. doi:10.1007/s10014-019-00343-0
6. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB (2009) Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol 95 (3):377-382. doi:10.1007/s11060-009-9935-z
7. Li ZH, Zhou Y, Ding YX, Guo QL, Zhao L (2019) Roles of integrin in tumor development and the target inhibitors. Chin J Nat Med 17 (4):241-251. doi:10.1016/S1875-5364(19)30028-7
8. Campbell ID, Humphries MJ (2011) Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol 3 (3). doi:10.1101/cshperspect.a004994
9. Lv Z, Yang Y, Yang C (2020) Integrin alpha7 correlates with worse clinical features and prognosis, and its knockdown inhibits cell proliferation and stemness in tongue squamous cell carcinoma. Int J Oncol 56 (1):69-84. doi:10.3892/ijo.2019.4927
10. Bai X, Gao C, Zhang L, Yang S (2019) Integrin alpha7 high expression correlates with deteriorative tumor features and worse overall survival, and its knockdown inhibits cell proliferation and invasion but increases apoptosis in breast cancer. J Clin Lab Anal 33 (8):e22979. doi:10.1002/jcla.22979
11. Xia D, Chen B, Yang X (2019) Correlation of integrin alpha 7 with clinicopathological characteristics and survival profiles, as well as its regulatory role in cell proliferation, apoptosis, and stemness in non-small-cell lung cancer. J Clin Lab Anal 33 (8):e22973. doi:10.1002/jcla.22973
12. Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A, Patrizii M, Warnken U, Schnolzer M, Ciolfi A, Di Stefano C, Biffoni M, Ricci-Vitiani L, Pallini R, De Maria R (2017) Integrin alpha7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell 21 (1):35-50 e39. doi:10.1016/j.stem.2017.04.009
13. Chen Y, Wang Y, Cai Z, Fan X, Zhang Y (2020) Integrin alpha7 is overexpressed and correlates with higher pathological grade, increased T stage, advanced TNM stage as well as worse survival in clear cell renal cell carcinoma patients: A retrospective study. J Clin Lab Anal 34 (1):e23034. doi:10.1002/jcla.23034
14. Huang J, Tian Y, Chen J (2018) Overexpression of integrin alpha7 correlates with advanced disease condition and poor prognosis in rectal cancer patients. Int J Clin Exp Pathol 11 (9):4630-4636
15. Zhang Q, Xu B, Chen J, Chen F, Chen Z (2020) Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. J Clin Lab Anal 34 (3):e23082. doi:10.1002/jcla.23082
16. Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW, Ma S, Xie D, Guan XY (2016) Integrin alpha7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat Commun 7:13568. doi:10.1038/ncomms13568
17. Ge JC, Wang YX, Chen ZB, Chen DF (2020) Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma. Cell Signal 66:109465. doi:10.1016/j.cellsig.2019.109465
18. Barzegar Behrooz A, Syahir A, Ahmad S (2019) CD133: beyond a cancer stem cell biomarker. J Drug Target 27 (3):257-269. doi:10.1080/1061186X.2018.1479756
19. Aghajani M, Mansoori B, Mohammadi A, Asadzadeh Z, Baradaran B (2019) New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation. J Cell Physiol 234 (12):21642-21661. doi:10.1002/jcp.28824
20. Rabea AR, Elshahid AR, Elhakim MS, Hashish YH, Jafferany M, Elsaie ML (2020) Therapeutic implications of immunohistochemical expression pattern of the cancer stem cell marker (nestin) in basal and squamous cell carcinomas. Dermatol Ther 33 (6):e13921. doi:10.1111/dth.13921
21. Costa CD, Justo AA, Kobayashi PE, Story MM, Palmieri C, Laufer Amorim R, Fonseca-Alves CE (2019) Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer. Int J Biochem Cell Biol 108:21-28. doi:10.1016/j.biocel.2019.01.002
22. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6):803-820. doi:10.1007/s00401-016-1545-1
23. Shen S, Yao Y (2021) A-kinase interacting protein 1 is sufficiently expressed and positively associates with WHO grade, meanwhile predicts unfavorable overall survival independently in glioma patients. Medicine (Baltimore) 100 (4):e20426. doi:10.1097/MD.0000000000020426
24. Abd El hafez A, El-Hadaad HA (2014) Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer. Ann Diagn Pathol 18 (2):58-62. doi:10.1016/j.anndiagpath.2013.11.004
25. McClure MJ, Ramey AN, Rashid M, Boyan BD, Schwartz Z (2019) Integrin-alpha7 signaling regulates connexin 43, M-cadherin, and myoblast fusion. Am J Physiol Cell Physiol 316 (6):C876-C887. doi:10.1152/ajpcell.00282.2018
26. Al Amri WS, Baxter DE, Hanby AM, Stead LF, Verghese ET, Thorne JL, Hughes TA (2020) Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants. Breast Cancer Res Treat 183 (3):607-616. doi:10.1007/s10549-020-05836-7
27. Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, Liu Q, Wang RF (2018) Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Front Immunol 9:2924. doi:10.3389/fimmu.2018.02924
28. Zhu K, Xie V, Huang S (2020) Epigenetic regulation of cancer stem cell and tumorigenesis. Adv Cancer Res 148:1-26. doi:10.1016/bs.acr.2020.05.001
29. Ludwig K, Kornblum HI (2017) Molecular markers in glioma. J Neurooncol 134 (3):505-512. doi:10.1007/s11060-017-2379-y